Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
A-METHAPRED vs ACETASOL HC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It also induces lipocortin synthesis, inhibits phospholipase A2, and reduces immune cell activity.
Acetic acid (otic solution) is antibacterial and antifungal; hydrocortisone is a corticosteroid that suppresses inflammation.
Allergic reactions (severe or disabling),Dermatologic diseases (e.g., pemphigus, exfoliative dermatitis),Endocrine disorders (e.g., congenital adrenal hyperplasia, nonsuppurative thyroiditis),Gastrointestinal diseases (e.g., ulcerative colitis, Crohn's disease),Hematologic disorders (e.g., autoimmune hemolytic anemia, thrombocytopenia),Neoplastic diseases (e.g., leukemia, lymphoma),Nervous system disorders (e.g., multiple sclerosis exacerbations),Ophthalmic diseases (e.g., allergic conjunctivitis, optic neuritis),Renal diseases (e.g., nephrotic syndrome, lupus nephritis),Respiratory diseases (e.g., asthma exacerbations, sarcoidosis),Rheumatic disorders (e.g., rheumatoid arthritis, acute gouty arthritis),Organ transplantation (as part of immunosuppressive regimen)
Treatment of superficial bacterial infections of the external auditory canal (swimmer's ear),Treatment of fungal infections of the external ear
Initial 4-48 mg/day oral in divided doses, tapered. For pulse therapy: 1 g IV daily for 3 days.
5 drops into the affected ear(s) 3-4 times daily. Each drop contains 2% acetic acid and 1% hydrocortisone.
2-3 hours (terminal); clinical effect persists longer due to intracellular receptor binding.
Hydrocortisone has a terminal elimination half-life of approximately 1.5-2 hours. Acetic acid has a half-life of minutes due to rapid metabolism. Clinical context: dosing interval is typically 3-4 times daily for otic use.
Primarily hepatic via CYP3A4 enzyme system, with minor contributions from other pathways.
Not extensively metabolized; undergoes minimal hepatic metabolism.
Renal (mainly as inactive metabolites); <5% unchanged. Biliary/fecal excretion is minimal.
Acetasol HC is a combination product containing hydrocortisone and acetic acid. Hydrocortisone is primarily metabolized in the liver and excreted renally as inactive metabolites; less than 1% is excreted unchanged. Acetic acid is rapidly metabolized via the tricarboxylic acid cycle and eliminated as carbon dioxide and water. Biliary/fecal elimination is negligible for both components.
74-90% bound primarily to corticosteroid-binding globulin (CBG) and albumin.
Hydrocortisone is approximately 90-95% bound to corticosteroid-binding globulin (CBG) and albumin. Acetic acid has negligible protein binding (<10%).
1.0-1.5 L/kg; indicates extensive tissue distribution.
Hydrocortisone Vd is approximately 0.3-0.5 L/kg, indicating distribution into total body water. Acetic acid Vd is approximately 0.4 L/kg. Clinical meaning: limited tissue distribution; primarily remains in extracellular fluid.
Oral: ~80%; IM: ~100%.
Otic: Bioavailability is approximately 10-20% via the ear canal due to slow permeation through tympanic membrane; systemic absorption is minimal (<10% of applied dose). Oral: Not applicable; product is for otic use only.
No specific dose adjustment required; use caution in severe renal impairment.
No renal adjustment required as systemic absorption is negligible.
No specific guidelines; caution in severe hepatic impairment.
No hepatic adjustment required as systemic absorption is negligible.
0.5-1.7 mg/kg/day or 5-25 mg/m²/day in divided doses.
Same as adult: 5 drops into affected ear(s) 3-4 times daily. Safety and efficacy in children under 2 years not established.
Lower initial doses recommended due to increased risk of osteoporosis, fluid retention, and immunosuppression.
No specific adjustment; use same adult dosing. Consider age-related skin thinning and potential for increased systemic absorption in cases of tympanic membrane perforation.
Corticosteroids, including methylprednisolone, may cause immunosuppression and increase susceptibility to infections. Live or live attenuated vaccines are contraindicated in patients receiving immunosuppressive doses. Administration of live vaccines may cause disseminated infection.
None
Increased risk of infections; monitor for signs of infection and avoid exposure to active infections.,Adrenal suppression may occur, especially with prolonged therapy; taper dosing gradually.,May cause fluid and electrolyte disturbances (e.g., sodium retention, potassium loss, hypertension).,Gastrointestinal perforation risk, especially in patients with inflammatory bowel disease or recent GI surgery.,Osteoporosis with long-term use.,Behavioral and mood disturbances (e.g., euphoria, depression, psychosis).,Cushing's syndrome with chronic use.,Exacerbation of diabetes mellitus, glaucoma, and cataracts.,High-dose therapy may cause acute myopathy, particularly in patients on neuromuscular blocking agents.
For otic use only; not for ophthalmic use,Prolonged use may result in overgrowth of non-susceptible organisms,Discontinue if sensitization or irritation occurs,Caution in patients with perforated tympanic membrane
Systemic fungal infections,Hypersensitivity to methylprednisolone or any component of the formulation,Administration of live or live attenuated vaccines in immunosuppressive doses,Idiopathic thrombocytopenic purpura (IM route only)
Hypersensitivity to any component,Perforated tympanic membrane,Viral or fungal infections of the ear (except when used for fungal infections as indicated)
Avoid grapefruit and grapefruit juice as they may increase methylprednisolone levels. Limit sodium intake to reduce fluid retention. Avoid alcohol due to increased risk of gastrointestinal bleeding. Maintain adequate calcium and vitamin D intake to prevent bone loss.
No known food interactions. Avoid excessive alcohol as it may impair immune response.
First trimester: Corticosteroids are associated with a small increased risk of oral clefts (odds ratio ~1.5). Second and third trimesters: Chronic use may lead to fetal adrenal suppression, intrauterine growth restriction, and preterm birth. Risk is dose- and duration-dependent.
ACETASOL HC (hydrocortisone 1% and acetic acid 2%) is an otic solution. Systemic absorption following topical otic application is minimal. No adequate and well-controlled studies in pregnant women. Animal reproduction studies with topical glucocorticoids have shown an increased risk of cleft palate and other malformations at high doses. Based on limited human data and low systemic exposure, use during pregnancy is generally considered low risk. However, as a precaution, avoid use in the first trimester unless clearly needed.
Prednisolone (active metabolite) is excreted into breast milk, with an M/P ratio approximately 5:1 to 20:1. The relative infant dose is estimated at <10% of maternal weight-adjusted dose. Monitor infant for adrenal suppression and growth. Nursing should be timed 3-4 hours after maternal dose.
Systemic absorption after otic application is minimal. It is not known whether hydrocortisone or acetic acid is excreted in human milk. M/P ratio is not available. Concentrations in milk are likely negligible. Use is considered compatible with breastfeeding.
Dose adjustment may be necessary due to increased clearance of prednisolone in pregnancy. Dose should be individualized, often with increased doses during pregnancy and reduced postpartum. No standard fixed adjustment; monitor clinical response.
No dose adjustment is necessary in pregnancy due to minimal systemic absorption. Pharmacokinetic changes in pregnancy are not expected to alter efficacy or safety of this topical otic preparation.
A-Methapred is a brand of methylprednisolone sodium succinate. For acute spinal cord injury, administer within 8 hours with a bolus of 30 mg/kg over 15 minutes, followed by a 45-minute pause, then 5.4 mg/kg/hour for 23 hours. Monitor for hyperglycemia, especially in diabetic patients; consider insulin sliding scale. Taper dose if used for >5 days to avoid adrenal insufficiency. Avoid abrupt discontinuation.
ACETASOL HC (acetic acid 2%, hydrocortisone 1%) is used for otitis externa. Acetic acid restores acidic p H of ear canal, inhibiting bacterial and fungal growth. Hydrocortisone reduces inflammation and pruritus. Ensure tympanic membrane is intact before use due to risk of ototoxicity with corticosteroids in middle ear. Do not use for more than 7 days. Shake well before instillation.
Do not stop taking this medication suddenly without consulting your doctor; dosage must be tapered gradually.,Report any signs of infection (fever, sore throat, cough) or unusual bleeding/bruising immediately.,Avoid live vaccines while on this medication.,Take with food or milk to reduce stomach upset.,Carry a medical alert card stating you are taking corticosteroids.,Do not miss doses; take exactly as prescribed.
Instill 3-4 drops into affected ear every 2-3 hours for 5-7 days.,Lie on side for 5 minutes after instillation to ensure coverage.,Avoid inserting cotton swabs or objects into the ear.,Discontinue if pain, worsening discharge, or rash occurs.,Do not use if ear drum is perforated or if you have a history of ear surgery.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about A-METHAPRED vs ACETASOL HC, answered by our medical review team.
A-METHAPRED is a Corticosteroid that works by Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It also induces lipocortin synthesis, inhibits phospholipase A2, and reduces immune cell activity.. ACETASOL HC is a Otic Anti-infective with Corticosteroid that works by Acetic acid (otic solution) is antibacterial and antifungal; hydrocortisone is a corticosteroid that suppresses inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between A-METHAPRED and ACETASOL HC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of A-METHAPRED is: Initial 4-48 mg/day oral in divided doses, tapered. For pulse therapy: 1 g IV daily for 3 days.. The standard adult dose of ACETASOL HC is: 5 drops into the affected ear(s) 3-4 times daily. Each drop contains 2% acetic acid and 1% hydrocortisone.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between A-METHAPRED and ACETASOL HC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. A-METHAPRED is classified as Category C. First trimester: Corticosteroids are associated with a small increased risk of oral clefts (odds ratio ~1.5). Second and third trimesters: Chronic use may lead to fetal adrenal sup. ACETASOL HC is classified as Category C. ACETASOL HC (hydrocortisone 1% and acetic acid 2%) is an otic solution. Systemic absorption following topical otic application is minimal. No adequate and well-controlled studies i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.